Technology
Splitting the MMR vaccine could lead to missed doses and increased illness among children, echoing past lessons from vaccine history.
Technology
FDA nixes a radiopharma drug by ITM Isotope Technologies, while Hims & Hers plans to enter the peptides market amidst evolving regulations.
Technology
Skylark Bio has initiated a clinical trial aimed at treating hearing loss in children with GJB2 mutations, following advancements in gene therapy.
Technology
MoonLake Immunotherapeutics faces scrutiny for vague disclosures on its autoimmune drug candidate, raising questions about its trial results’ credibility.
Technology
The recent Senate hearings on Covid-19's origins spotlight political distractions, while China's suppression of information remains a pivotal issue.
Technology
The NIH's proposed changes to funding eligibility may limit opportunities for international researchers on visas in the U.S. biomedical sector.
Technology
Replimune's new melanoma treatment gains FDA approval, while a Medicare policy change delays price negotiations for AbbVie drugs.
Technology
As Boston's biotech sector grapples with talent migration to California, new discoveries in Alzheimer's research signal both change and opportunity.
Technology
As AI tools proliferate in healthcare, the erosion of physician autonomy raises questions about clinical judgment, responsibility, and professional independence.
Technology
Felix Wong's biotech startup thrives in California's culture despite his Massachusetts roots and impressive academic pedigree.
Technology
Replimune's advanced melanoma drug, RP1, receives FDA approval after a challenging path, bringing hope to patients with a hefty price tag.
Technology
A recent Medicare policy change has postponed the price negotiations for a major AbbVie drug, potentially impacting taxpayers significantly.
Technology
A recent study reveals tau protein’s unexpected influence on cellular function, suggesting novel strategies for Alzheimer’s treatment.
Technology
The FDA has recently approved a new therapeutic drug and a vaccine, shaping the future direction of biotechnology and addressing pressing health needs.
Technology
The FDA has approved Takeda's Orzeyful, a new orexin receptor agonist that promises to improve daytime alertness for narcolepsy patients.